4 completed, 1 unknown. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 3 | Completed 2, Unknown 1 |
Follow APG101: new trials by email Literature Review of APG101 trials Research Report on APG101
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of CAN008 in Subjects With GBM CAN008, Placebo - Newly-diagnosed Glioblastoma | Phase 2 | Unknown | CANbridge Life Sciences Ltd. | 117 | 2021-10-10 | 2022-07-12 |
| NCT Neuro Master Match - N²M² (NOA-20) APG101, Alectinib, Idasanutlin - Glioblastoma, Adult | Phase 1 / Phase 2 | Completed | University Hospital Heidelberg | 228 | 2018-05-07 | 2023-09-28 |
| A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme CAN008 - Glioblastoma Multiforme | Phase 1 | Completed | CANbridge Life Sciences Ltd. | 10 | 2016-08-01 | 2018-11-08 |
| APG101 in Myelodysplastic Syndrome Treatment with APG101, Bone marrow collection, Blood drawings - Myelodysplastic Syndrome | Phase 1 | Completed | Apogenix GmbH | 20 | 2013-01-01 | 2016-08-24 |
| APG101 in Glioblastoma APG101, Blood drawing - Glioblastoma Multiforme | Phase 2 | Completed | Apogenix GmbH | 84 | 2009-12-01 | 2015-06-16 |
Glioblastoma (4) · Anemia (1) · Myelodysplastic Syndromes (1)
Apogenix GmbH (2) · CANbridge Life Sciences Ltd. (2) · University Hospital Heidelberg (1)
Germany (3) · Austria (1) · China (1) · Taiwan (1)
Florian Nolte, MD (1) · Wenbin Li, MD, PhD (1) · Wolfgang Wick, MD (1) · Wolfgang Wick, Prof. Dr. (1) · Ying Xu, MD (1)
2015 (1)